PriceTargets.com logo

Fate Therapeutics - FATE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.92
  • Forecasted Upside: 256.06%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.10 As of 12/4/2025 05:00 PM ET
▲ +0.02 (1.85%)

This chart shows the closing price for FATE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FATE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FATE

Analyst Price Target is $3.92
▲ +256.06% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $3.92, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 256.06% upside from the last price of $1.10.

This chart shows the closing price for FATE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in Fate Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/4/2025Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral
10/31/2025HC WainwrightUpgradeNeutral ➝ Buy$5.00
10/27/2025WedbushUpgradeNeutral ➝ Outperform$5.00 ➝ $7.00
10/27/2025Needham & Company LLCReiterated RatingHold ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/13/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$4.00 ➝ $2.50
6/12/2025Needham & Company LLCReiterated RatingHold ➝ Hold
5/14/2025BarclaysLower TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025Robert W. BairdLower TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025Needham & Company LLCReiterated RatingHold ➝ Hold
3/6/2025Stifel NicolausLower TargetHold ➝ Hold$5.00 ➝ $3.00
3/6/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00
3/6/2025WedbushReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
3/6/2025Needham & Company LLCReiterated RatingHold ➝ Hold
11/19/2024Needham & Company LLCReiterated RatingHold
11/18/2024Bank of AmericaUpgradeUnderperform ➝ Neutral
11/13/2024Needham & Company LLCReiterated RatingHold
11/12/2024WedbushReiterated RatingNeutral$5.00
8/22/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
8/14/2024Needham & Company LLCReiterated RatingHold
6/17/2024Piper SandlerUpgradeNeutral ➝ Overweight$4.00 ➝ $6.00
5/16/2024HC WainwrightLower TargetNeutral ➝ Neutral$7.00 ➝ $5.00
5/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$11.00 ➝ $9.00
5/10/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.00
5/10/2024Piper SandlerLower TargetNeutral ➝ Neutral$7.00 ➝ $4.00
5/6/2024WedbushReiterated RatingNeutral ➝ Neutral$7.00 ➝ $7.00
4/23/2024WedbushReiterated RatingNeutral ➝ Neutral$7.00
4/11/2024Needham & Company LLCReiterated RatingHold
3/28/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$2.00 ➝ $6.00
3/19/2024HC WainwrightReiterated RatingNeutral$7.00
2/27/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.00
2/27/2024BarclaysBoost TargetOverweight ➝ Overweight$6.00 ➝ $10.00
2/27/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$6.00 ➝ $7.00
2/27/2024WedbushBoost TargetNeutral ➝ Neutral$3.00 ➝ $7.00
2/27/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform
11/20/2023MizuhoLower TargetBuy ➝ Buy$12.00 ➝ $8.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $3.00
11/9/2023BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$5.40 ➝ $6.00
11/9/2023WedbushReiterated RatingNeutral ➝ Neutral$6.00 ➝ $3.00
11/9/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.00
9/7/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$5.00
8/16/2023Truist FinancialReiterated RatingHold ➝ Hold$7.00
8/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
8/10/2023BarclaysLower TargetOverweight ➝ Overweight$12.00 ➝ $6.00
8/9/2023BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$6.00 ➝ $5.40
5/4/2023Stifel NicolausLower Target$5.30 ➝ $5.00
5/4/2023Cantor FitzgeraldLower Target$8.00 ➝ $5.00
3/27/2023Wells Fargo & CompanyReiterated RatingEqual Weight$6.00
3/2/2023CitigroupBoost TargetBuy$9.00 ➝ $10.00
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$10.00
3/1/2023Piper SandlerLower Target$12.00 ➝ $7.00
1/24/2023HC WainwrightDowngradeBuy ➝ Neutral$115.00 ➝ $7.00
1/9/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
1/6/2023Morgan StanleyLower TargetEqual Weight$35.00 ➝ $8.00
1/6/2023CowenDowngradeOutperform ➝ Market Perform
1/6/2023Truist FinancialReiterated RatingBuy ➝ Hold$46.00 ➝ $7.00
1/6/2023Leerink PartnersLower TargetOutperform$62.00 ➝ $10.00
1/6/2023Bank of AmericaDowngradeBuy ➝ Underperform
1/6/2023WedbushDowngradeOutperform ➝ Neutral$42.00 ➝ $7.00
1/6/2023Stifel NicolausDowngradeBuy ➝ Hold
1/6/2023CowenDowngradeOutperform ➝ Market Perform
1/6/2023Piper SandlerDowngradeOverweight ➝ Neutral$71.00 ➝ $12.00
1/6/2023BMO Capital MarketsDowngradeOutperform ➝ Market Perform$20.00 ➝ $7.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$16.00
1/3/2023GuggenheimDowngradeBuy ➝ Neutral
12/22/2022OppenheimerDowngradeOutperform ➝ Market Perform
12/15/2022The Goldman Sachs GroupInitiated CoverageSell$10.00
12/13/2022Truist FinancialLower TargetBuy$51.00 ➝ $46.00
12/13/2022Leerink PartnersLower TargetOutperform$64.00 ➝ $62.00
12/12/2022OppenheimerLower Target$90.00 ➝ $65.00
11/24/2022Leerink PartnersSet Target$64.00
11/16/2022CitigroupLower TargetBuy$87.00 ➝ $80.00
11/4/2022Cantor FitzgeraldReiterated RatingOverweight$98.00 ➝ $45.00
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$42.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
9/9/2022Morgan StanleyLower TargetEqual Weight$45.00 ➝ $35.00
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight$90.00
8/4/2022OppenheimerLower Target$135.00 ➝ $90.00
7/28/2022Needham & Company LLCInitiated CoverageHold
7/11/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$50.00 ➝ $47.00
6/2/2022Robert W. BairdInitiated CoverageNeutral$28.00
5/23/2022Piper SandlerLower TargetOverweight$113.00 ➝ $71.00
4/13/2022Truist FinancialLower Target$125.00 ➝ $75.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/4/2022HC WainwrightLower TargetBuy$122.00 ➝ $115.00
3/1/2022WedbushBoost TargetOutperform$74.00 ➝ $77.00
1/11/2022HC WainwrightReiterated RatingBuy$122.00
1/3/2022GuggenheimLower Target$107.00 ➝ $78.00
12/15/2021Morgan StanleyLower TargetEqual Weight$74.00 ➝ $62.00
12/15/2021HC WainwrightBoost TargetBuy$121.00 ➝ $122.00
12/15/2021WedbushUpgradeNeutral ➝ Outperform$71.00 ➝ $74.00
12/7/2021CowenInitiated CoverageOutperform
11/8/2021CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $87.00
11/8/2021Leerink PartnersLower TargetOutperform$118.00 ➝ $115.00
11/5/2021Roth CapitalLower TargetNeutral$90.00 ➝ $60.00
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$77.00
8/23/2021HC WainwrightReiterated RatingBuy$121.00
8/5/2021HC WainwrightBoost TargetBuy$120.00 ➝ $121.00
8/5/2021Leerink PartnersLower TargetOutperform$120.00 ➝ $118.00
7/9/2021Stifel NicolausReiterated RatingBuy$116.00
6/7/2021HC WainwrightUpgradeNeutral ➝ Buy$120.00
5/14/2021WedbushDowngradeOutperform ➝ Neutral
5/7/2021WedbushUpgradeNeutral ➝ Outperform$88.00
4/26/2021Jefferies Financial GroupInitiated CoverageBuy$145.00
3/12/2021Leerink PartnersBoost TargetOutperform$58.00 ➝ $121.00
3/4/2021WedbushReiterated RatingOutperform ➝ Neutral
3/4/2021Wells Fargo & CompanyBoost TargetOverweight$84.00 ➝ $130.00
2/26/2021Truist FinancialBoost Target$85.00 ➝ $135.00
2/26/2021Bank of AmericaInitiated CoverageBuy$115.00
2/26/2021WedbushDowngradeOutperform ➝ Neutral
2/25/2021Roth CapitalBoost Target$30.00 ➝ $90.00
2/25/2021Cantor FitzgeraldBoost TargetOverweight$86.00 ➝ $98.00
2/25/2021MizuhoBoost TargetBuy$88.00 ➝ $109.00
2/17/2021Piper SandlerBoost TargetOverweight$99.00 ➝ $116.00
2/11/2021CitigroupDowngradeBuy ➝ Neutral
1/27/2021HC WainwrightReiterated RatingNeutral$108.00
1/25/2021BMO Capital MarketsBoost TargetMarket Perform$57.00 ➝ $88.00
1/19/2021OppenheimerReiterated RatingOutperform$70.00 ➝ $135.00
1/15/2021BarclaysBoost TargetPositive ➝ Overweight$110.00 ➝ $130.00
12/21/2020Stifel NicolausBoost TargetBuy$79.00 ➝ $118.00
12/17/2020BarclaysBoost TargetOverweight$80.00 ➝ $110.00
12/8/2020MizuhoBoost TargetBuy$40.00 ➝ $88.00
12/7/2020BMO Capital MarketsBoost TargetMarket Perform$43.00 ➝ $57.00
12/7/2020Wells Fargo & CompanyBoost TargetOverweight$61.00 ➝ $84.00
12/7/2020WedbushBoost TargetOutperform$55.00 ➝ $88.00
12/7/2020Smith Barney CitigroupBoost Target$63.00 ➝ $76.00
12/7/2020Piper SandlerBoost TargetOverweight$71.00 ➝ $99.00
12/7/2020OppenheimerBoost TargetOutperform$60.00 ➝ $70.00
12/7/2020Leerink PartnersBoost TargetOutperform$34.00 ➝ $58.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/8/2025
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/6/2025
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 4 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.10
Low: $1.05
High: $1.12

50 Day Range

MA: $1.25
Low: $0.96
High: $1.65

52 Week Range

Now: $1.10
Low: $0.66
High: $2.93

Volume

1,414,050 shs

Average Volume

1,331,115 shs

Market Capitalization

$126.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Fate Therapeutics?

The following equities research analysts have issued research reports on Fate Therapeutics in the last year: Barclays PLC, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Robert W. Baird, Stifel Nicolaus, Wall Street Zen, Wedbush, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for FATE.

What is the current price target for Fate Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Fate Therapeutics in the last year. Their average twelve-month price target is $3.92, suggesting a possible upside of 256.1%. Wedbush has the highest price target set, predicting FATE will reach $7.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $2.00 for Fate Therapeutics in the next year.
View the latest price targets for FATE.

What is the current consensus analyst rating for Fate Therapeutics?

Fate Therapeutics currently has 1 sell rating, 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FATE, but not buy more shares or sell existing shares.
View the latest ratings for FATE.

What other companies compete with Fate Therapeutics?

Other companies that are similar to Fate Therapeutics include Opthea, enGene, Bicycle Therapeutics, Altimmune and Lyell Immunopharma. Learn More about companies similar to Fate Therapeutics.

How do I contact Fate Therapeutics' investor relations team?

Fate Therapeutics' physical mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 875-1800 and its investor relations email address is [email protected]. The official website for Fate Therapeutics is www.fatetherapeutics.com. Learn More about contacing Fate Therapeutics investor relations.